| Literature DB >> 33133591 |
Hishyar Azo Najeeb1, Bayar Ahmad Qasim2, Ayad Ahmad Mohammed3.
Abstract
BACKGROUND: Thyroid dysfunction has a negative impact on coronary artery diseases (CAD) through several changes in its risk factors like dyslipidemia, glucose intolerance, and components of metabolic syndrome. Parental history of premature CAD may be an important risk factor for their offspring.Entities:
Keywords: Coronary artery diseases; High-sensitivity CRP; Lipid peroxidation by-product; Malondialdehyde; Retinol binding Protein-4
Year: 2020 PMID: 33133591 PMCID: PMC7588661 DOI: 10.1016/j.amsu.2020.10.034
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801
Baseline characteristics of cases and controls.
| Variables | Hypothyroid patients (n = 135) | Euthyroid Subjects (n = 100) | P.value |
|---|---|---|---|
| Age in years | 32.6 ± 5.7 | 31.0 ± 7.1 | 0.07 |
| Parental history of CAD Yes/No | 45/90 * | 12/88 | 0.001 |
| RBP-4(ng/ml) | 8.0 ± 4.8 | 5.7 ± 3.6 | 0.03 |
| TSH(mIU/L) | 18.3 ± 13.6 | 2.1 ± 1.0 | 0.001 |
| T4(nmol/L) | 76.3 ± 26.9 | 87.7 ± 16.3 | 0.001 |
| Hs-CRP(mg/L) | 7.2 ± 4.6 | 3.8 ± 2.7 | 0.001 |
| Fasting serum insulin(μU/ml) | 13.7 ± 9.8 | 8.5 ± 7.1 | 0.007 |
| HOMA-IR | 3.2 ± 2.0 | 1.7 ± 1.0 | 0.001 |
| HOMA- β cell. % | 52.5 ± 23.4 | 35.6 ± 14.0 | 0.04 |
| Fasting serum glucose(mg/dl) | 108.6 ± 26.2 | 82.4 ± 19.9 | 0.001 |
| Total serum cholesterol(mg/dl) | 227.5 ± 56.9 | 172.0 ± 21.3 | 0.001 |
| Serum triglyceride(mg/dl) | 161.7 ± 69.7 | 127.8 ± 55.2 | 0.001 |
| HDL-cholesterol(mg/dl) | 38.6 ± 8.9 | 47.9 ± 5.7 | 0.004 |
| LDL-cholesterol(mg/dl) | 150.0 ± 34.6 | 98.5 ± 0.5 | 0.001 |
| LDL-Ch/HDL-Ch (ratio) | 3.6 ± 1.0 | 2.6 ± 0.5 | 0.01 |
| Serum MDA(nmol/L) | 1.9 ± 0.5 | 1.0 ± 0.4 | 0.02 |
| Values are Mean ± Standard Deviation unless indicated otherwise | |||
Fig. 1Distribution of positive parental history of coronary artery disease by thyroid status.
Fig. 2Retinol Binding Protein-4 levels by thyroid status.
Distribution of related risk factors by thyroid status.
| Risk factors | Overt hypothyroid patients (n = 47) | Subclinical hypothyroid Patients (n = 88) | Euthyroid subjects (n = 100) |
|---|---|---|---|
| Positive parental history of CAD | 18 (38.3%)** | 27 (30.7%)** | 12 (12.0%) |
| Central obesity | 29 (61.7%)* | 39 (44.3%)* | 32 (32.0%) |
| Obesity and/or overweight | 37 (78.7%)* | 65 (73.9%)* | 58 (58.0%) |
| Hyperlipidemia | 42 (89.4%)* | 58 (65.9%)* | 16 (16.0%) |
| Glucose intolerance | 14 (29.6%)* | 18 (20.5%)* | 2 (2.0%) |
| Insulin resistance | 10 (21.3%)** | 13 (14.8%)** | 1 (1.0%) |
| Hypertension | 8 (17.0%)* | 5 (5.7%)* | 4 (4.0%) |
| Metabolic syndrome | 13 (27.6%)** | 23 (26.1%)** | 4 (4.0%) |
| Based on X2 test, *p < 0.01, **p < 0.001 | |||
Mean ± SD of the variables assessed in hypothyroid patients classified by parental history of CAD.
| Variables | Patients with positive history (n = 45) | Patients with negative history (n = 90) | P value * |
|---|---|---|---|
| RBP-4 (ng/ml) | 9.9 ± 4.7 | 6.5 ± 4.5 | 0.01 |
| TSH(mIU/L) | 18.3 ± 11.9 | 17.6 ± 9.2 | 0.5 |
| T4 (nmol/L) | 74.8 ± 25.7 | 76.7 ± 27.2 | 0.6 |
| Hs-CRP (mg/L) | 8.5 ± 4.0 | 6.6 ± 4.8 | 0.01 |
| Fasting serum insulin (μU/ml) | 15.4 ± 10.5 | 12.8 ± 9.4 | 0.2 |
| HOMA-IR | 3.4 ± 2.3 | 3.0 ± 2.4 | 0.4 |
| HOMA- β cell. (%) | 59.9 ± 23.1 | 48.6 ± 31.2 | 0.09 |
| Fasting serum glucose (mg/dl) | 101.2 ± 20.3 | 99.4 ± 24.5 | 0.6 |
| Total serum cholesterol (mg/dl) | 254.8 ± 52.9 | 213.8 ± 48.5 | 0.001 |
| Serum triglyceride (mg/dl) | 192.4 ± 61.6 | 146.4 ± 62.7 | 0.001 |
| HDL-cholesterol (mg/dl) | 42.7 ± 7.8 | 44.0 ± 9.4 | 0.4 |
| LDL-cholesterol (mg/dl) | 167.9 ± 63.6 | 141.2 ± 42.1 | 0.04 |
| LDL-Ch/HDL-Ch (ratio) | 4.0 ± 1.7 | 3.4 ± 1.4 | 0.02 |
| Serum MDA (nmol/L) | 2.1 ± 1.4 | 1.6 ± 0.6 | 0.03 |
Mean ± SD of the variables assessed in overt and subclinical hypothyroid patients classified by parental history of CAD.
| Variables | Overt hypothyroid patients | Subclinical hypothyroid patients | ||
|---|---|---|---|---|
| Positive history (n = 18) | Negative history (n = 29) | Positive history (n = 27) | Negative history (n = 61) | |
| R.B.P-4(ng/ml) | 9.5 ± 6.1 | 8.5 ± 4.6 | 8.7 ± 2.6 * | 6.1 ± 2.3 |
| TSH(mIU/L) | 43.7 ± 31.4 | 42.3 ± 29.1 | 6.0 ± 1.5 | 5.9 ± 1.4 |
| T4(nmol/L) | 54.7 ± 26.5 | 65.2 ± 36.4 | 81.0 ± 20.2 | 85.0 ± 19.7 |
| Hs-CRP(mg/L) | 9.0 ± 5.2 | 8.0 ± 6.7 | 7.7 ± 3.5 | 6.2 ± 3.4 |
| Fasting serum insulin(μU/ml) | 16.7 ± 11.8 | 15.0 ± 11.4 | 12.9 ± 8.1 | 11.0 ± 7.6 |
| HOMA-IR | 3.8 ± 2.3 | 3.6 ± 3.0 | 2.8 ± 1.6 | 2.5 ± 2.1 |
| HOMA-%β-cell | 66.8 ± 56.2 | 53.9 ± 47.6 | 50.8 ± 40.3 | 41.0 ± 30.2 |
| Fasting serum glucose(mg/L) | 111.3 ± 31.2 | 95.6 ± 12.7 | 101.0 ± 29.8 | 97.2 ± 18.7 |
| Total Cholesterol(mg/dL) | 326.2 ± 92.5* | 246.3 ± 61.0 | 244.4 ± 67.5 * | 2001 ± 35.0 |
| Triglyceride(mg/dL) | 309.4 ± 155.1* | 190.3 ± 62.5 | 187.2 ± 61.6 * | 131.4 ± 53.2 |
| HDL-Ch.(mg/dL) | 37.9 ± 7.2 | 44.7 ± 13.2 | 42.0 ± 7.9 | 43.5 ± 7.8 |
| LDL-Ch.(mg/dL) | 184.9 ± 75.6* | 146.1 ± 39.4 | 155.3 ± 65.8 * | 130.5 ± 30.8 |
| LDL-Ch/HDLCh(Ratio) | 4.8 ± 1.8* | 3.7 ± 1.0 | 3.8 ± 1.7 * | 3.1 ± 1.1 |
| Serum MDA(nmol/L) | 1.9 ± 0.8 | 1.6 ± 0.7 | 1.5 ± 0.3 | 1.2 ± 0.6 |
| Based on | ||||
Distribution of related risk factors in hypothyroid patients classified by parental history of CAD, n (%).
| Risk factors | Patient with positive history (n = 45) | Patient with negative history (n = 90) | P.value* |
|---|---|---|---|
| Central obesity | 33 (73.3%) | 35 (38.9%) | 0.001 |
| Obesity and/or overweight | 40 (88.9%) | 62 (68.8%) | 0.01 |
| Hyperlipidemia | 39 (86.7%) | 61 (67.8%) | 0.04 |
| Glucose intolerance | 13 (28.9%) | 19 (21.1%) | 0.4 |
| Insulin resistance | 11 (24.4%) | 12 (13.3%) | 0.1 |
| Hypertension | 8 (17.7%) | 5 (5.6%) | 0.052 |
| Metabolic syndrome | 23 (51.1%) | 13 (14.4%) | 0.001 |
| * Based on X2 test | |||
Distribution of related risk factors in overt and subclinical hypothyroid patients classified by parental history of CAD, n (%). The comparison between hypothyroid patients classified by gender is shown in Table 7.
| Variables | Overt hypothyroid patients | Subclinical hypothyroid patients | ||
|---|---|---|---|---|
| Positive history (n = 18) | Negative history (n = 29) | Positive history (n = 27) | Negative history (n = 61) | |
| Central obesity | 15 (83.3%)* | 14 (48.2%) | 18 (66.7%)* | 21 (34.4%) |
| Obesity and/or overweight | 16 (88.9%) | 21 (72.4%) | 24 (88.8%)* | 41 (67.2%) |
| Hyperlipidemia | 17 (94.4%) | 25 (86.2%) | 22 (81.5%)* | 36 (59.0%) |
| Glucose intolerance | 6 (33.3%) | 8 (27.5%) | 7 (25.9%) | 11 (18.0%) |
| Insulin resistance | 7 (38.9%)* | 3 (10.3%) | 4 (14.8%) | 9 (14.7%) |
| Hypertension | 6 (33.3%)* | 2 (6.9%) | 2 (7.4%) | 3 (4.9%) |
| Metabolic syndrome | 8 (44.4%)* | 5 (17.5%) | 15 (55.6%)* | 8 (13.1%) |
| Based on X2 test, *P < 0.05 | ||||
Mean ± SD of variables assessed in hypothyroid patients classified by gender.
| Variables | Hypothyroid men (n = 21) | Hypothyroid women (114) | P.value* |
|---|---|---|---|
| RBP-4(ng/ml) | 9.7 ± 4.9 | 7.5 ± 4.7 | 0.2 |
| TSH(mIU/L) | 27.5 ± 12.1 | 16.5 ± 11.7 | 0.06 |
| T4(nmol/L) | 70.4 ± 31.8 | 77.3 ± 25.9 | 0.3 |
| Hs-CRP(mg/L) | 8.3 ± 4.9 | 7.0 ± 4.6 | 0.2 |
| Fasting serum insulin(μU/ml) | 11.3 ± 6.7 | 12.1 ± 10.2 | 0.2 |
| HOMA-IR | 2.6 ± 1.5 | 3.2 ± 2.5 | 0.3 |
| HOMA- β cell % | 39.7 ± 25.7 | 54.3 ± 5.0 | 0.08 |
| Fasting serum glucose (mg/dl) | 96.7 ± 14.6 | 101.3 ± 25.5 | 0.2 |
| Total serum cholesterol(mg/dl) | 243.7 ± 54.4 | 224.5 ± 57.1 | 0.1 |
| Serum triglyceride(mg/dl) | 173.3 ± 70.5 | 159.9 ± 68.8 | 0.4 |
| HDL-cholesterol(mg/dl) | 44.9 ± 7.3 | 43.3 ± 9.2 | 0.3 |
| LDL-cholesterol(mg/dl) | 164.5 ± 52.2 | 147.4 ± 51.3 | 0.1 |
| LDL-Ch/HDL-Ch (ratio) | 3.7 ± 1.1 | 3.6 ± 1.6 | 0.7 |
| Serum MDA(nmol/L) | 1.8 ± 0.5 | 1.7 ± 1.0 | 0.9 |
| * Based on | |||
Distribution of related risk factors in hypothyroid females classified by parental history of CAD, n (%). Mean ± standard deviation of serum RBP-4 and related risk factor concentrations according to parental history in females are shown in Table 9.
| Risk factors | Patient with positive history (n = 38) | Patient with negative history (n = 76) | P value* |
|---|---|---|---|
| Central obesity | 29 (76.3%) | 30 (39.5%) | 0.001 |
| Obesity and/or overweight | 36 (94.7%) | 52 (68.4%) | 0.004 |
| Hyperlipidemia | 35 (92.1%) | 51 (67.1%) | 0.001 |
| Glucose intolerance | 12 (31.6%) | 14 (18.4%) | 0.1 |
| Insulin resistance | 7 (18.4%) | 11 (14.5%) | 0.7 |
| Hypertension | 6 (15.7%) | 3 (3.9%) | 0.001 |
| Metabolic syndrome | 18 (50.0%) | 13 (22.4%) | 0.001 |
| * Based on X2 test | |||
Mean ± SD of the variables assessed in female hypothyroid patients classified by parental history of CAD.
| Variables | Female patients with positive history (n = 38) | Female patients with Negative history (n = 76) | P.value * |
|---|---|---|---|
| R.B.P-4(ng/mL) | 9.3 ± 4.1 | 6.6 ± 4.9 | 0.04 |
| TSH(mIU/L) | 16.9 ± 6.1 | 13.8 ± 8.7 | 0.07 |
| T4(nmol/L) | 76.7 ± 24.0 | 77.6 ± 6.9 | 0.8 |
| Hs-CRP(mg/L) | 8.0 ± 3.8 | 6.5 ± 4.9 | 0.04 |
| F.serum insulin(μU/ml) | 15.5 ± 10.8 | 13.4 ± 9.7 | 0.6 |
| HOMA-IR | 3.4 ± 2.4 | 3.1 ± 2.5 | 0.6 |
| HOMA-%β-cell | 60.9 ± 50.1 | 51.0 ± 42.7 | 0.3 |
| F.serum glucose(mg/L) | 101.9 ± 25.5 | 99.9 ± 25.8 | 0.6 |
| T.cholesterol(mg/dL) | 254.2 ± 33.5 | 209.7 ± 47.4 | 0.001 |
| Triglyceride(mg/dL) | 191.9 ± 45.1 | 143.4 ± 59.7 | 0.001 |
| HDL-ch.(mg/dL) | 42.0 ± 7.6 | 43.9 ± 9.8 | 0.2 |
| LDL-ch.(mg/dL) | 167.2 ± 65.5 | 137.5 ± 39.4 | 0.003 |
| LDL-ch/HDLch(Ratio) | 4.1 ± 1.8 | 3.3 ± 1.4 | 0.02 |
| Serum MDA(nmol/L) | 2.1 ± 1.5 | 1.6 ± 0.6 | 0.04 |
| * Based on | |||
Fig. 3ROC curve showing the tradeoff between sensitivity (true positive) and false positive (1-specificity) of all available cutoff values for RBP-4 in predicting hypothyroidism.
Validity parameters for RBP-4 test in predicting hypothyroidism.
| Positive if ≥ cutoff value | sensitivity | specificity | accuracy | PPV | NPV | LR |
|---|---|---|---|---|---|---|
| 5.8 | 94.1 | 2.8 | 62.2 | 64.3 | 20.5 | 1.82 |
| 6.1 | 87.9 | 6.4 | 59.5 | 63.7 | 22.2 | 1.81 |
| 6.3 | 81.5 | 10.4 | 56.7 | 62.9 | 23.2 | 1.60 |
| 6.4 | 75.0 | 15.1 | 54.1 | 62.9 | 24.5 | 1.31 |
| 6.5 | 68.4 | 20.4 | 51.7 | 61.6 | 25.7 | 1.24 |
| 6.6 | 61.8 | 26.8 | 49.6 | 61.1 | 27.3 | 1.02 |
| 6.7 | 55.0 | 34.4 | 47.8 | 61.0 | 29.0 | 0.89 |
| 7.0 | 47.9 | 42.5 | 46.0 | 60.8 | 30.4 | 0.87 |
| 7.3 | 40.5 | 51.2 | 44.2 | 60.7 | 31.6 | 0.85 |
| 7.5 | 32.9 | 60.3 | 42.4 | 60.6 | 32.5 | 0.83 |
| 7.7 | 25.1 | 69.7 | 40.7 | 60.4 | 33.3 | 0.82 |
| 8.0 | 17.0 | 79.5 | 38.8 | 60.3 | 33.9 | 0.82 |
| 8.3 | 8.6 | 89.6 | 36.8 | 60.1 | 34.4 | 0.83 |
Spearman's coefficient of RBP-4 with related variables in hypothyroid patients.
| Groups | W.C | BMI | TSH | T4 | F.insuln | Homa-IR | Homa-β% | FBS | T.Ch | TG | HDl | LDL | hsCRP | MDA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total(n = 135) hypothyroidism | r | r | r | r | r | r | r | r | r | r | r | r | r | r |
| Overt(n = 47) hypothyroidism | r | r | r | r | r | r | r | r | r | r | r | r | r | r |
| Subclinical(n = 88) hypothyroidism | r | r | r | r | r | r | r | r | r | r | r | r | r | r |
Fig. 4Correlation between RBP-4 and TSH in hypothyroid patients (n = 135).
Multiple linear regression analysis of related variables with RBP-4.
| Independent variables | R | P.value |
|---|---|---|
| Waist circumference | 0.547 | 0.005 |
| Body mass index | 0.795 | 0.001 |
| Systolic Bp. | 0.379 | 0.07 |
| Diastolic | 0.210 | 0.12 |
| TSH | 0.789 | 0.001 |
| T4 | 0.200 | 0.33 |
| Fasting serum insulin | 0.457 | 0.04 |
| HOMA-IR | 0.465 | 0.03 |
| HOMA-β%-cell function | 0.453 | 0.04 |
| Total s.cholesterol | 0.876 | 0.001 |
| Serum triglyceride | 0.772 | 0.001 |
| HDL-cholesterol | 0.361 | 0.06 |
| LDL-cholesterol | 0.573 | 0.04 |
| LDL-ch/HDL-ch | 0.416 | 0.03 |
| MDA | 0.528 | 0.007 |
| Hs-CRP | 0.610 | 0.001 |
| Fasting serum glucose | 0.404 | 0.04 |
Multivariate analysis of factors presumed to present a risk for coronary artery disease in hypothyroid patients compared to euthyroid subjects.
| Variables | Hypothyroidism n (135) | Euthyroidism n (100) | X2 | OR (95%CI) |
|---|---|---|---|---|
| Positive parental history of CAD | 45 (33.3%)* | 12 (12.0%) | 13.0 | 3.7 (1.82–7.39) |
| Central obesity | 68 (58.4%)* | 32 (32%) | 7.2 | 2.1 (1.26–3.7) |
| Obesity and/or overweight | 102 (75.6%)* | 58 (58.0%) | 7.3 | 2.2 (1.28–3.91) |
| Hyperlipidemia | 100 (74.0%)* | 16 (16.0%) | 75.2 | 15.0 (7.76–28.99) |
| Glucose intolerance | 32 (23.7%)* | 2 (2.0%) | 20.1 | 15.2 (3.55–65.23) |
| Insulin resistance | 23 (17.0%)* | 1 (1.0%) | 14.4 | 20.3 (12.7–153.31) |
| Hypertension | 13 (10.6%) | 4 (4.0%) | 1.9 | 2.6 (0.81–8.09) |
| Metabolic syndrome | 36 (26.7%)* | 4 (4.0%) | 19.3 | 8.7 (2.99–25.46) |
| *p < 0.05 | ||||
Multivariate analyses of factors presumed to present a risk for coronary artery disease between patients with subclinical hypothyroidism and euthyroid subjects.
| Variables | Subclinical hypothyroidism n (88) | Euthyroidism n (100) | X2 | OR (95%CI) |
|---|---|---|---|---|
| Positive parental history of CAD | 27 (30.7%)* | 12 (12.0%) | 8.8 | 3.3 (1.53–6.90) |
| Central obesity | 39 (44.3%) | 32 (32%) | 2.5 | 1.7 (0.93–3.06) |
| Obesity and/or overweight | 65 (73.9%)* | 58 (58.0%) | 4.5 | 2.1 (1.10–3.80) |
| Hyperlipidemia | 58 (65.9%)* | 16 (16.0%) | 46.8 | 10.2 (5.08–20.30) |
| Glucose intolerance | 18 (20.5%)* | 2 (2.0%) | 14.9 | 12.6 (2.83–56.06) |
| Insulin resistance | 13 (14.8%)* | 1 (1.0%) | 10.9 | 17.2 (2.20–134.1) |
| Hypertension | 5 (5.7%) | 4 (4.0%) | 0.04 | 1.5 (0.38–5.56) |
| Metabolic syndrome | 23 (26.1%)* | 4 (4.0%) | 16.9 | 8.5 (2.81–25.70) |
| *p < 0.05 | ||||
| Area | Std. Error | Asymptotic | Asymptotic 95% confidence interval | |
| Lower bound | Upper bound | |||
| .675 | .078 | .037 | .523 | .827 |